National Oilwell Varco
NOV
$20.07
-2.24%
NOV Inc. designs, manufactures, and sells a broad portfolio of equipment and components for the oil and gas industry, including rig equipment, downhole tools, drill pipe, and well casing, organized into two reportable segments: energy products and services and energy equipment. The company is a scaled, globally diversified supplier to major integrated oil companies, national oil companies, independent operators, and drilling contractors, with international markets contributing nearly two-thirds of annual revenue, positioning it as a bellwether for global drilling and completions activity rather than a pure-play on any single basin. The current investor narrative centers on the durability of an international and offshore-led upcycle against a still-soft North American land market, with management's 20% dividend increase announced in February 2026 signaling confidence in cash generation even as headline revenue growth has stalled. Debate now hinges on whether cost discipline, a leaner capital structure, and rising offshore project awards can offset margin pressure from a fourth-quarter 2025 net loss, with sell-side opinion notably split between bulls citing backlog conversion and bears flagging valuation and end-market cyclicality.…
NOV
National Oilwell Varco
$20.07
Related headlines
Investment Opinion: Should I buy NOV Today?
We assign a Hold rating on NOV. The core thesis is that the stock is fairly valued after its 58.5% one-year run, with the market already pricing a sharp earnings recovery that has yet to appear in reported results. The analyst consensus rating of 'buy' with an average target price of $22.24 implies only 5.4% upside, suggesting limited near-term return potential. While the valuation is undemanding on sales and book value, the lack of revenue growth and thin margins warrant caution.
The supporting evidence for a Hold is balanced. On the positive side, NOV trades at 0.665x sales and 0.928x book, well below its historical multiples, and offers a 15% free cash flow yield with a conservative debt-to-equity of 0.373. The 20% dividend increase and $85 million of quarterly buybacks demonstrate management's confidence in cash generation. However, revenue declined 1.34% year over year in Q4 2025, net margin is just 1.66%, and ROE is a paltry 2.31%. The forward PE of 16.49x assumes EPS of $1.92, a 2.4x increase from trailing levels, which is a high bar given the stagnant top line.
The biggest risks that could invalidate the thesis are a failure to achieve the consensus earnings recovery, a further deterioration in North American land activity, and multiple compression if oil prices fall. We would upgrade to Buy if revenue growth accelerates above 5% year over year and operating margins expand above 8%, or if the stock pulls back to the $17-$18 range, offering a better risk/reward. We would downgrade to Sell if revenue declines persist, margins fall below 5%, or the company cuts its dividend. Relative to its history and peers, NOV appears undervalued on asset-based metrics but fairly valued on earnings-based metrics, reflecting the market's skepticism about the recovery.
Sign up to view all
NOV 12-Month Price Forecast
NOV presents a balanced risk/reward profile. The valuation is attractive on sales and book value, and the cash flow generation is strong, but the company has yet to demonstrate revenue growth or margin improvement. The stock is trading near its 52-week high, and the analyst consensus target implies only 5.4% upside, suggesting limited near-term catalysts. We would upgrade to bullish if revenue growth accelerates above 5% and margins expand, or if the stock pulls back to the $17-$18 range. We would downgrade to bearish if revenue declines persist or if the dividend is cut. Given the split analyst community and the uncertain earnings recovery, a neutral stance is appropriate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on National Oilwell Varco's 12-month outlook, with a consensus price target around $22.24 and implied upside of +10.8% versus the current price.
Average Target
$22.24
0 analysts
Implied Upside
+10.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $26
Analyst target range
Nineteen analysts cover NOV, with a consensus recommendation of "buy" and a recommendation mean of 2.5 on a scale where lower is more bullish, indicating a genuinely split rather than uniformly positive stance. The average target price is $22.24, which against the current $21.10 implies roughly 5.4% upside — a modest expected return that suggests the sell-side sees the stock as fairly valued after its 58.5% one-year run. The consensus leans cautiously bullish, but the 2.5 mean and the presence of a Goldman Sachs Sell rating alongside multiple Neutral and Market Perform calls indicate that conviction is far from universal.
The target range spans $17.00 to $26.00, a spread of $9.00, or 53% of the current price, which signals meaningful disagreement about the earnings recovery path. The high target of $26.00 implies roughly 23% upside and would require multiple expansion toward 1.2x book or 13.5x forward earnings, likely predicated on accelerating international and offshore orders converting into margin expansion. The low target of $17.00 implies about 19% downside and prices in continued revenue stagnation, margin compression, and a retest of the July lows. Recent institutional actions show a mild positive drift — Barclays upgraded to Equal Weight from Underweight in February 2026, and Stifel, TD Cowen, and Susquehanna maintain Buy or Positive ratings — but Goldman Sachs reiterated Sell in March 2026 and Piper Sandler, Citigroup, and BMO remain Neutral, so the balance of recent activity is neutral-to-mixed rather than decisively bullish. The consensus 2026 EPS estimate of $1.92 (range $1.81-$1.98) and revenue estimate of $10.06 billion (range $9.60-$10.30 billion) imply roughly 15% revenue growth over the trailing run rate, a forecast that the flat recent quarterly trend has yet to validate.
Drowning in data?
Find the real signal!
Bulls vs Bears: NOV Investment Factors
The bear case currently has stronger near-term evidence: revenue is stagnant, Q4 2025 delivered a net loss, and the stock trades just below its 52-week high with decelerating momentum. However, the bull case rests on a compelling valuation and cash-flow story—0.665x sales, 0.928x book, and a 15% FCF yield—that could unlock significant upside if the earnings recovery materializes. The single most important tension is whether the consensus 2026 EPS of $1.92 is achievable; if it is, the forward PE of 16.49x is reasonable, but if revenue growth remains elusive, the stock is vulnerable to a sharp re-rating. Analyst sentiment is split, with a 2.5 recommendation mean and a wide target range, underscoring that conviction is low on both sides. Ultimately, the investment hinges on the pace of international and offshore order conversion, which has yet to show up in reported results.
Bullish
- Deep Value on Sales and Book: NOV trades at just 0.665x trailing sales and 0.928x book value, a steep discount to its own 2022-2023 PS range of 2.0x-3.0x and below the 1.0x book threshold. The market is pricing the business at a fraction of its historical multiple despite a $8.74 billion revenue run-rate and a $5.81 billion market cap.
- Massive Free Cash Flow Yield: Trailing free cash flow of $876 million against a $5.81 billion market cap implies an FCF yield near 15%, supported by Q4 2025 operating cash flow of $573 million and capital expenditure of only $101 million. This cash generation comfortably funds the 20% dividend increase and $85 million of quarterly buybacks.
- Fortress Balance Sheet: Debt-to-equity is a conservative 0.373 and the current ratio is a healthy 2.42, with cash rising to $1.552 billion in Q4 2025 from $1.207 billion at the start of the quarter. This liquidity provides a cushion to weather cyclical downturns and continue returning capital.
- Analyst Consensus Buy with Upside: Nineteen analysts rate NOV a 'buy' with a recommendation mean of 2.5 and an average target price of $22.24, implying 5.4% upside from $21.10. The high target of $26.00 suggests 23% upside if international and offshore orders accelerate.
Bearish
- Revenue Stagnation and Net Loss: Q4 2025 revenue of $2.277 billion declined 1.34% year over year, and the trailing four-quarter run-rate of $8.74 billion shows no acceleration. The quarter produced a net loss of $78 million, or -$0.21 per share, driven by a $147 million tax expense against just $66 million of pre-tax income.
- Razor-Thin and Deteriorating Margins: Trailing net margin is only 1.66% and operating margin is 6.45%, with Q4 2025 operating margin compressing to 7.11% from 8.97% a year earlier. ROE of 2.31% and ROA of 3.45% are well below what investors should demand from a cyclical industrial.
- Valuation Already Prices Recovery: The forward PE of 16.49x assumes earnings roughly 2.4x from trailing levels, consistent with the $1.92 consensus EPS estimate versus trailing EPS of $0.025. If the recovery fails to materialize, the stock could revert toward its 52-week low of $12.29, implying 42% downside.
- Split Analyst Conviction: The recommendation mean of 2.5 and the presence of a Goldman Sachs Sell rating alongside multiple Neutral calls indicate far from universal bullishness. The target range of $17.00 to $26.00 spans 53% of the current price, reflecting deep disagreement on the earnings path.
NOV Technical Analysis
NOV is in a sustained uptrend, with the shares up 58.53% over the past year versus a 16.22% gain for SPY, a relative strength advantage of 42.31 percentage points. At $21.10, the stock is trading at approximately 91.4% of its 52-week range of $12.29 to $21.93, sitting just 3.8% below the high and 71.7% above the low. That positioning signals strong momentum but also leaves limited near-term headroom before the stock tests overhead resistance, and it raises the risk of profit-taking for momentum-oriented holders. The 180-day price series confirms the trend: the stock bottomed near $17.79 on July 6, 2026, and has since climbed roughly 18.6% into early September, with higher lows punctuating the advance.
Short-term momentum is positive but decelerating relative to the longer-term move. NOV gained 0.91% over the past month, outperforming SPY's -1.06% by 1.97 percentage points, yet the three-month change is -0.14% versus SPY's +3.04%, producing a relative strength deficit of 3.18 percentage points over that window. This divergence — a strong 12-month trend with a flat-to-negative quarter — suggests the stock consolidated through the summer rather than reversing, and the August rebound from $19.76 to $21.71 indicates buyers defended the $19.50-$20.00 zone. Year-to-date the stock is up 28.58% against SPY's 12.08%, and the six-month gain of 14.49% slightly trails SPY's 15.40%, reinforcing that the bulk of outperformance was earned in late 2025 and early 2026 rather than recently.
Key technical levels are well defined: support sits at the 52-week low of $12.29, with a more actionable intermediate floor near the July low of $17.79 and the August consolidation base around $19.50-$20.00, while resistance is the 52-week high of $21.93, just 3.9% above the current $21.10. A decisive breakout above $21.93 would confirm trend continuation and likely invite momentum capital, whereas a breakdown below $19.50 would signal a failed breakout and expose the $17.79 area. With a beta of 0.944, NOV is slightly less volatile than the broad market, which is unusual for an energy-equipment name and implies position sizing can be somewhat more aggressive than a high-beta cyclical would warrant; the maximum drawdown of -17.06% over the period further underscores contained downside relative to typical oilfield-services peers.
Beta
0.94
0.94x market volatility
Max Drawdown
-17.1%
Largest decline past year
52-Week Range
$12-$22
Price range past year
Annual Return
+54.7%
Cumulative gain past year
| Period | NOV Return | S&P 500 |
|---|---|---|
| 1m | -3.0% | -1.0% |
| 3m | +7.6% | +2.0% |
| 6m | +7.4% | +17.4% |
| 1y | +54.7% | +15.0% |
| ytd | +22.3% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NOV Fundamental Analysis
Revenue has stagnated at a low level, with fourth-quarter 2025 revenue of $2.277 billion declining 1.34% year over year, and the trailing four-quarter run rate of roughly $8.74 billion reflecting a business that is treading water rather than growing. The sequential path tells the story: revenue moved from $2.103 billion in Q1 2025 to $2.188 billion in Q2, $2.176 billion in Q3, and $2.277 billion in Q4, a range-bound pattern with no clear acceleration. The lone disclosed segment datapoint, royalty revenue of $19 million, is immaterial to the consolidated picture, so the investment case rests on the consolidated top line and the mix shift toward international and offshore activity, which carries better pricing than North American land. Until revenue reaccelerates, the equity story depends on margin and cash-flow execution rather than growth.
Profitability is thin and deteriorating at the bottom line. Q4 2025 produced a net loss of $78 million, or -$0.21 per diluted share, a sharp reversal from net income of $160 million in Q4 2024, driven by a $147 million income tax expense against just $66 million of pre-tax income and a gross margin of 20.29%. Gross margin has been remarkably stable in the 18.9%-21.3% band across the last eight quarters, but operating margin compressed to 7.11% in Q4 2025 from 8.97% in Q4 2024, and the trailing net margin is only 1.66% with an operating margin of 6.45%. For a capital-goods supplier in oilfield services, a low-20s gross margin is structurally typical, but the sub-2% net margin leaves almost no cushion, and the company's ROE of 2.31% and ROA of 3.45% are well below what investors should demand from a cyclical industrial.
Balance-sheet and cash-flow metrics are the strongest part of the story. Debt-to-equity is a conservative 0.373, the current ratio is a healthy 2.42, and trailing free cash flow is $876 million, which against a market cap of roughly $5.81 billion implies an FCF yield near 15% — a striking figure that explains the 4.69x price-to-cash-flow multiple and the 12.05x price-to-free-cash-flow ratio. Q4 2025 operating cash flow was $573 million with capital expenditure of only $101 million, and cash on the balance sheet rose to $1.552 billion from $1.207 billion at the start of the quarter. The company is funding itself internally, returning capital via $27 million of dividends and $85 million of buybacks in Q4 alone, and the 20% dividend increase is comfortably covered by cash generation even though the payout ratio of 131% against GAAP earnings looks stretched on an earnings basis.
Quarterly Revenue
$2.3B
2025-12
Revenue YoY Growth
-1.3%
YoY Comparison
Gross Margin
20.3%
Latest Quarter
Free Cash Flow
$876000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NOV Overvalued?
Because NOV's trailing net income is positive but de minimis — EPS of $0.025 and a trailing PE of 40.08x — the PE ratio is technically applicable but economically misleading, so the more informative primary metric is the price-to-sales ratio of 0.665x, supported by EV/Sales of 1.021x and EV/EBITDA of 8.07x. The forward PE of 16.49x against the trailing 40.08x implies the market expects earnings to roughly 2.4x from current levels, consistent with the consensus 2026 EPS estimate of $1.92 versus the trailing $0.025. That gap is the crux of the valuation debate: the market is pricing a sharp earnings recovery that has not yet appeared in reported results, and the PEG ratio of -0.53 is not meaningful given the depressed trailing earnings base.
Relative to the oil and gas equipment and services sector, NOV screens cheap on asset-based and sales-based measures. The price-to-book ratio of 0.928x means the stock trades below book value, and the 0.665x PS ratio is well under the 2.0x-3.0x range the company carried in 2022-2023, implying a discount of roughly 70% to its own recent sales multiple. The EV/EBITDA of 8.07x is moderate for a capital-goods cyclical and sits below the 10x-12x range typically awarded to higher-quality industrial compounders. The discount appears justified by the 1.66% net margin, 2.31% ROE, and negative revenue growth, but the 15% free-cash-flow yield and 0.37 debt-to-equity suggest the market is pricing balance-sheet strength and cash generation at a deep discount to earnings power.
Historically, NOV's valuation sits near the bottom of its own multi-year band. The PS ratio has compressed from 3.94x in Q4 2022 and 3.60x in Q1 2024 to 0.665x today, while price-to-book has fallen from 1.60x in Q4 2022 to 0.928x. The trailing PE of 40.08x is elevated only because earnings are depressed, and the historical PE series shows the same distortion — 8.85x in Q4 2024, 29.18x in Q3 2025, and negative in Q4 2025. The combination of a below-book price, a sub-1x sales multiple, and a double-digit free-cash-flow yield suggests the market is pricing either a prolonged downcycle or structural margin impairment; if earnings normalize toward the $1.92 consensus estimate, the forward multiple of 16.49x would represent a reasonable, not stretched, entry point.
PE
40.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 3x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.1x
Enterprise Value Multiple
Investment Risk Disclosure
NOV's financial and operational risks are significant. The company generated a Q4 2025 net loss of $78 million, or -$0.21 per share, as a $147 million income tax expense overwhelmed $66 million of pre-tax income. Trailing net margin is a razor-thin 1.66%, leaving almost no cushion for cost inflation or pricing pressure, and operating margin compressed to 7.11% in Q4 2025 from 8.97% a year earlier. Revenue is concentrated in cyclical oil and gas equipment, with nearly two-thirds from international markets, exposing the company to geopolitical and currency risks. The payout ratio of 131% against GAAP earnings, while covered by cash flow, signals that the dividend is not supported by accounting profits and could be at risk if cash generation falters.
Market and competitive risks are equally pressing. NOV trades at a forward PE of 16.49x, which already prices a sharp earnings recovery; if that recovery stalls, multiple compression could be severe. The stock's beta of 0.944 is slightly below the market, but as an oilfield-services name it remains exposed to oil price volatility and capex cycles. Competition from larger diversified industrials and specialized technology providers could pressure pricing, particularly in the North American land market, which remains soft. Recent news highlights the 20% dividend increase as a sign of confidence, but also underscores the need for sustained cash flow growth amid energy sector volatility. The split analyst community—with a Goldman Sachs Sell rating and a 2.5 recommendation mean—reflects these uncertainties.
The worst-case scenario would involve a global economic slowdown that curbs oil demand, leading to reduced drilling activity and delayed offshore projects. In that scenario, revenue could decline further, margins could compress below 5%, and the company could swing to a full-year loss. The stock could retest its 52-week low of $12.29, representing a 42% decline from the current $21.10. The analyst low target of $17.00 implies a more moderate 19% downside, but a severe downturn could push shares below that level. Given the maximum drawdown of -17.06% over the past 180 days, a 40%+ drawdown is plausible in a deep cyclical downturn, especially with the stock trading near its 52-week high.
FAQ
The most severe risk is earnings disappointment: Q4 2025 revenue declined 1.34% year over year and the company posted a net loss of $78 million, so if the consensus EPS of $1.92 is not achieved, the stock could fall sharply. Second, margin compression is a concern, with operating margin at 6.45% and net margin at 1.66%, leaving little cushion for cost inflation. Third, the dividend payout ratio of 131% against GAAP earnings is stretched, and while covered by cash flow, a downturn could force a cut. Fourth, the stock is exposed to oil price volatility and global drilling activity, with a beta of 0.944. Finally, the analyst community is split, with a Goldman Sachs Sell rating and a wide target range of $17-$26, indicating uncertainty. A retest of the 52-week low of $12.29 would represent a 42% loss from current levels.
Our 12-month forecast for NOV has three scenarios. The base case (55% probability) targets $21-$23, assuming modest revenue growth of 3-5% and stable oil prices. The bull case (25% probability) targets $24-$26, driven by accelerating international and offshore orders and margin expansion. The bear case (20% probability) targets $12.29-$17.00, assuming a global slowdown, revenue declines, and margin compression. The most likely scenario is the base case, where NOV trades around the analyst average target of $22.24, reflecting a fair valuation. The key assumption is that oil prices remain in the $65-$75 range and the company delivers on its earnings recovery. However, given the stagnant revenue trend, the risk is skewed to the downside if the recovery disappoints.
NOV appears undervalued on asset-based and sales-based metrics but fairly valued on earnings-based metrics. The price-to-sales ratio of 0.665x is well below its historical range of 2.0x-3.0x, and the price-to-book ratio of 0.928x is below 1.0x, suggesting the market is pricing a prolonged downcycle. However, the forward PE of 16.49x assumes EPS of $1.92, a 2.4x increase from trailing levels, which is a high bar given stagnant revenue. The EV/EBITDA of 8.07x is moderate for a capital-goods cyclical. The market is pricing in a sharp earnings recovery; if that fails to materialize, the stock could be overvalued at current levels. Relative to peers, NOV screens cheap on sales and book, but the discount is justified by its 1.66% net margin and 2.31% ROE.
NOV is a reasonable buy for value-oriented investors with a long time horizon, but it is not a compelling short-term trade. The stock trades at 0.665x sales and 0.928x book, with a 15% free cash flow yield, which provides a margin of safety. However, revenue declined 1.34% year over year in Q4 2025, and the company reported a net loss of $78 million, so the earnings recovery is uncertain. Analyst consensus target of $22.24 implies only 5.4% upside, and the recommendation mean of 2.5 indicates split conviction. The biggest downside risk is a retest of the 52-week low of $12.29, representing 42% downside. For risk-tolerant investors who believe in the international offshore upcycle, NOV offers deep value, but it requires patience and a tolerance for volatility.
NOV is better suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company is in a cyclical industry with a beta of 0.944, and its earnings recovery is likely to take time. The dividend yield of 3.27% and the 20% dividend increase provide income while waiting for the cycle to turn. Short-term trading is risky because the stock is near its 52-week high and momentum has decelerated, with a three-month relative strength deficit of 3.18 percentage points versus SPY. The wide analyst target range of $17-$26 and the split recommendation mean of 2.5 indicate low near-term visibility. Long-term investors can benefit from the deep-value valuation and strong cash flow, but they must tolerate volatility and the possibility of a retest of the 52-week low.
